CP 465022 hydrochloride
Cat. No. 2932
Chemical Name: 3-(2-Chlorophenyl)-2-[2-[6-[(diethy
Biological ActivitySelective, non-competitive AMPA antagonist (IC50 = 25 nM in rat cortical neurons) that displays potent anticonvulsant activity. Also significantly blocks the persistent component of Nav1.6 channel activity. Brain penetrant and orally active.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Welch et al (2008) Traditional AMPA receptor antagonists partially block Nav1.6-mediated persistent current. Neuropharmacology 55 1165. PMID: 18687344.
Menniti et al (2003) CP-465,022, a selective noncompetitive AMPA receptor antagonist, blocks AMPA receptors but is not neuroprotective in vivo. Stroke 34 171. PMID: 12511770.
Lazaro et al (2002) Functional characterization of CP-465,022, a selective, noncompetitive AMPA receptor antagonist. Neuropharmacology 42 143. PMID: 11804610.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses CP 465022 hydrochloride from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: CP 465022 hydrochloride, supplier, Selective, non-competitive, AMPA, antagonists, Glutamate, Receptors, iGluR, Ionotropic, CP465022, hydrochloride, Tocris Bioscience, AMPA Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
NMDA receptor modulator; metabolite of Ketamine hydrochloride (Cat. No.3131)2S,6S-Hydroxynorketamine hydrochloride
Potent AMPA agonist; antidepressant2R,6R-Hydroxynorketamine hydrochloride
Potent AMPA agonist; lacks ketamine-related side effects(R)-Norketamine hydrochloride
NMDA receptor modulator; metabolite of Ketamine hydrochloride (Cat. No.3131).PEAQX tetrasodium salt
Potent NMDA receptor antagonist; NR2A selective
One Day Symposium
March 1, 2017
Amsterdam, The Netherlands